CHICAGO – February 20, 2018 – GE Healthcare announced today its being recognized as one of Fast Company’s Most Innovative Companies of 2018. As a leading maker of medical diagnostic equipment, GE Healthcare was honored on the Top 10 Most Innovative Companies in Biotech list for the launch of its latest mammography system, Senographe Pristina.... Read more
CHICAGO – February 20, 2018 – GE Healthcare announced today its being recognized as one of Fast Company’s Most Innovative Companies of 2018. As a leading maker of medical diagnostic equipment, GE Healthcare was honored on the Top 10 Most Innovative Companies in Biotech list for the launch of its https://www.genewsroom.com/press-releases/ge-healthcare-named-fast-companys-top-10-most-innovative-companies-biotech-putting Read more
Basel, 12 February 2018 Phase II data support potential for Roche’s novel anti-VEGF/anti-angiopoietin-2 bispecific antibody, RG7716, for people with diabetic macular edema RG7716 is the first bispecific antibody designed specifically for the treatment of retinal eye diseases RG7716 demonstrated clinically meaningful and statistically significant improvements in visual acuity Key secondary and exploratory anatomical outcomes were... Read more
Basel, 06 February 2018 Phase III IMmotion151 study showed Roche’s TECENTRIQ® (atezolizumab) and Avastin® (bevacizumab) reduced the risk of disease worsening or death by 26 percent in certain people with advanced kidney cancer TECENTRIQ and Avastin met co-primary endpoint of improvement in investigator-assessed progression-free survival (PFS) compared with sunitinib for people whose disease expressed PD-L1... Read more
Basel, 06 February 2018 Phase III IMmotion151 study showed Roche’s TECENTRIQ® (atezolizumab) and Avastin® (bevacizumab) reduced the risk of disease worsening or death by 26 percent in certain people with advanced kidney cancer TECENTRIQ and Avastin met co-primary endpoint of improvement in investigator-assessed progression-free survival (PFS) compared with sunitinib for people whose disease expressed PD-L1... Read more
Basel, 06 February 2018 Phase III IMmotion151 study showed Roche’s TECENTRIQ® (atezolizumab) and Avastin® (bevacizumab) reduced the risk of disease worsening or death by 26 percent in certain people with advanced kidney cancer TECENTRIQ and Avastin met co-primary endpoint of improvement in investigator-assessed progression-free survival (PFS) compared with sunitinib for people whose disease expressed PD-L1... Read more
Basel, 06 February 2018 Phase III IMmotion151 study showed Roche’s TECENTRIQ® (atezolizumab) and Avastin® (bevacizumab) reduced the risk of disease worsening or death by 26 percent in certain people with advanced kidney cancer TECENTRIQ and Avastin met co-primary endpoint of improvement in investigator-assessed progression-free survival (PFS) compared with sunitinib for people whose disease expressed PD-L1... Read more
Solution offers researchers the power to perform glycan screening of large sample cohorts enabling better decisions in clone selection and cell culture optimization January 30, 2018 Framingham, MA — SCIEX, a global leader in life science analytical technologies, today announced the launch of the new C100HT for qualitative glycan screening in biopharma. Combined with SCIEX’s award-winning... Read more
Shimadzu Corporation has released the Nexera Mikros, a micro flowrate-compatible liquid chromatograph mass spectrometer. The Nexera Mikros maintains the durability and operability of liquid chromatography mass spectrometry (LC-MS) systems while providing at least ten times the sensitivity. In recent years, in the field of pharmaceutical development, analysis has occasionally been performed on trace amounts of... Read more
Germantown, Maryland, and Hilden, Germany, January 18, 2018 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) has approved a PMA supplement extending the indications for use of QIAGEN’s therascreen® EGFR RGQ PCR Kit as a companion diagnostic to guide the use of Boehringer Ingelheim’s... Read more